Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study

Abstract Objective Coronavirus disease 2019 (COVID-19) is a major challenge facing the world. Certain guidelines issued by National Health Commission of People's Repubilic China recommend intravenous immunoglobulin (IVIG) for adjuvant treatment COVID-19. However, there lack clinical evidence to support use IVIG. Methods This single-center retrospective cohort study included all adult patients with laboratory-confirmed severe COVID-19 in Respiratory and Critical Care Unit Dabie Mountain Regional Medical Center, China. Patient information, including demographic data, laboratory indicators, glucocorticoids IVIG, hospital mortality, application mechanical ventilation, length stay was collected. The primary outcome composite end point, death ventilation. secondary stay. Results Of 285 confirmed COVID-19, 113 severely ill were this study. Compared non-IVIG group, more IVIG group reached point [12 (25.5%) vs 5 (7.6%), P = 0.008] had longer periods [23.0 (19.0–31.0) 16.0 (13.8–22.0), < 0.001]. After adjusting confounding factors, differences outcomes between two groups not statistically significant ( 0.167), however, 0.041). Conclusion Adjuvant therapy did improve in-hospital mortality rates or need ventilation patients. Our does